Achieve Life Sciences (ACHV) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Myriad Genetics (MYGN) over the past year, gaining 125.9% versus a loss of 44.3%. Over five years, ACHV leads with a -8.0% price change compared with -86.4% for MYGN. Achieve Life Sciences is the larger company by market cap ($764.0 million vs $412.2 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | MYGN |
|---|---|---|
| Share price | $7.41 | $4.31 |
| Market cap | $763.99M | $412.25M |
| 1-day change | +3.06% | +2.62% |
| YTD return | +49.09% | -29.92% |
| 1-year return | +125.91% | -44.32% |
| 5-year return | -7.95% | -86.42% |
| EPS (TTM) | $-1.69 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $8.59 |
| 52-week low | $2.62 | $2.74 |
| Distance from 52-week high | -14.24% | -49.83% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +90.96% | -9.28% |
| Average volume | 1.42M | 2.04M |
| Shares outstanding | 103.10M | 95.65M |
| Employees | 28 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed MYGN by 170.2 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
ACHV vs MYGN FAQ
Which is bigger, Achieve Life Sciences or Myriad Genetics?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $763.99M compared with $412.25M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, ACHV or MYGN?
ACHV returned +125.91% over the past 12 months, compared with -44.32% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Myriad Genetics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.